FDA Grants Priority Review for Gilead's New HIV Treatment, Potentially Transforming Care
Gilead Sciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for a novel HIV treatment combining bictegravir and lenacapavir. This investigational, once-daily single-tablet regimen is designed for adults with virological suppression. The FDA has granted a priority review, setting a Prescription Drug User Fee Act (PDUFA) action date for August 27, 2026. The combination aims to provide sustained virologic suppression with a high barrier to resistance, particularly benefiting those with complex treatment histories or comorbidities. The NDA is supported by positive Phase 3 trial data, demonstrating efficacy in maintaining virological suppression and improving patient-reported treatment satisfaction. 
